J
Josep M. Grinyó
Researcher at University of Barcelona
Publications - 339
Citations - 17719
Josep M. Grinyó is an academic researcher from University of Barcelona. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 65, co-authored 325 publications receiving 16263 citations. Previous affiliations of Josep M. Grinyó include Bellvitge University Hospital & Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Reduced exposure to calcineurin inhibitors in renal transplantation.
Henrik Ekberg,Helio Tedesco-Silva,Alper Demirbas,Stefan Vitko,Björn Nashan,A. Gurkan,Raimund Margreiter,Christian Hugo,Josep M. Grinyó,Ulrich Frei,Yves Vanrenterghem,Pierre Daloze,Philip F. Halloran +12 more
TL;DR: In this paper, the authors evaluated the efficacy and relative toxic effects of four immunosuppressive regimens: cyclosporine, mycophenolate mofetil, and corticosteroids.
Journal Article
Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection
Josep M. Grinyó,Carl-Gustav Groth,Rudolf Pichlmayr,Sa Sadek,Yves Vanrenterghem,M Behrend,R Luck,Francesc Moreso,J Peeters,J Rodicio,J Morales,Dagfinn Albrechtsen,P Fauchald,Sameh S. Sadek,J. P. A. Lodge,Jp Soulillou,Diego Cantarovich,van Willem Son,Adam Tegzess,Karl-Heinz Wagner,J Erhard,Christina Brattström,Lars Mjörnstedt,M. Wiesel,S. Carl,Hh Neumayer,Hauser,Peter Lang,B Bourgeon,Gunnar Tufveson,G. Gannedahl,Henrik Ekberg,N. Persson,A Tarantino,M Campise,G Thiel,M Zeiler,R Hene,G Ligtenberg,A Morgan,K Rigg,Hooftman L,K Hutchinson +42 more
TL;DR: MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated, although the 3 g dose was somewhat less well tolerated.
Journal ArticleDOI
Costimulation blockade with belatacept in renal transplantation.
Flavio Vincenti,Christian P. Larsen,Antoine Durrbach,Thomas Wekerle,Björn Nashan,Gilles Blancho,Philippe Lang,Josep M. Grinyó,Philip F. Halloran,Kim Solez,David Hagerty,Elliott Levy,Wenjiong Zhou,Kannan Natarajan,Bernard Charpentier +14 more
TL;DR: Belatacept, an investigational selective costimulation blocker, did not appear to be inferior to cyclosporine as a means of preventing acute rejection after renal transplantation and may preserve the glomerular filtration rate and reduce the rate of chronic allograft nephropathy.
Journal ArticleDOI
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)
Antoine Durrbach,José Osmar Medina Pestana,Thomas C. Pearson,Flavio Vincenti,Valter Duro Garcia,Josep M. Campistol,M. del Carmen Rial,Sander Florman,A. Block,G. Di Russo,J Xing,P. Garg,Josep M. Grinyó +12 more
TL;DR: ECD kidney transplant recipients treated with belatacept‐based immunosuppression achieved similar patient/graft survival, better renal function, had an increased incidence of PTLD, and exhibited improvement in the cardiovascular/metabolic risk profile versus cyclosporine‐treated patients.
Journal ArticleDOI
Early Experience with Dual Kidney Transplantation in Adults using Expanded Donor Criteria
Giuseppe Remuzzi,Josep M. Grinyó,Piero Ruggenenti,M Beatini,Edward H. Cole,Edgar L. Milford,Barry M. Brenner +6 more
TL;DR: Dual transplants of marginal kidneys are as safe and tolerated as single transplants, and possibly offer an improved filtration power without exposing the recipient to enhanced risk of delayed renal function recovery, acute allograft rejection, or major surgical complications.